ArticleMolecular cancer therapeutics2024

Preclinical Characterization of ARX517, a Site-Specific Stable PSMA-Targeted Antibody-Drug Conjugate for the Treatment of Metastatic Castration-Resistant Prostate Cancer.

Lillian K Skidmore et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.